Start-up’s product is timely as 20 per cent patients picked up infections from hospitals. Biomoneta, has developed and deployed a powerful air decontamination technology to destroy microbes across the entire spectrum of bacteria, fungi, and virus families, including covid-19.
Now to commercialise this air decontamination product Zebox, the Centre for Cellular and Molecular Platform (C-CAMP), which has been supporting many of the country’s covid-19 innovations, has collaborated with Applied Materials and Biomoneta.
According to C-CAMP, at a time when hospitals have become infection hotspots and 20 per cent of patients with covid-19 are reported to have caught (HAI), there is a significant need for such a technology not just in India or in low or middle-income Countries but across the world.
“An effective decontamination technology that improves infection control in healthcare spaces must kill or contaminating microbes instead of merely trapping, operate continuously and safely in human presence, and require near-zero manual intervention while operating close to the source of infection or contamination. To the best of our knowledge, no other technology being evaluated globally meets all these requirements. Zebox is therefore, a first-in-its-class with the potential to be a global lifesaver,” C-CAMP stated. Zebox was designed primarily to prevent HAIs, specifically multi-drug resistant () bacterial infections. Zebox combines state-of-the-art electronics and air flow design with novel anti-microbial materials to effectively destroy a billion plus microbes across the entire spectrum of bacteria, fungi, and virus families, including covid-19.
Zebox was deployed in a few leading hospitals like St. John’s Hospital and Medical College, and . During these trials the product met with a clear need for increased effectiveness against highly infectious, pathogenic viruses that can cause epidemics, especially in children, C-CAMP said. “Biomoneta’s novel Zebox technology is probably one of the most impactful solutions today. We have supported Biomoneta with powerful engineering simulations done from our Bengaluru facility which was further independently validated by our team in Mumbai for microbial load, pre and post deployment,”said Srinivas Satya, country president, Applied Materials India
